Comparative Pharmacology
Head-to-head clinical analysis: AVINZA versus LEVORPHANOL TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVINZA versus LEVORPHANOL TARTRATE.
AVINZA vs LEVORPHANOL TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVINZA (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia by altering pain perception and emotional response to pain.
Levorphanol is a potent opioid analgesic that acts as a mu-opioid receptor agonist. It also has NMDA receptor antagonist activity, inhibits norepinephrine and serotonin reuptake, and acts as a sigma receptor agonist, contributing to its analgesic effects and reduced tolerance development.
Oral, 30 mg once daily (q24h) for opioid-naïve patients; titrate based on response. Maximum daily dose 160 mg. Administer with food to minimize peak effects.
2 mg orally every 6-8 hours as needed for pain; for opioid-tolerant patients, doses up to 4 mg orally every 6-8 hours may be used. Parenterally: 1-2 mg subcutaneously or intramuscularly every 6-8 hours; may be given intravenously at 0.5-1 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life of morphine is approximately 1.5-2 hours; however, due to the extended-release formulation, the effective half-life is prolonged to about 9-11 hours, allowing once-daily dosing.
11-16 hours; extended in hepatic impairment (up to 30 hours).
Primarily renal (approximately 90% as morphine metabolites, mainly morphine-3-glucuronide and morphine-6-glucuronide); biliary/fecal excretion accounts for less than 10%.
Renal: approximately 30% as unchanged drug and 50% as glucuronide conjugates; fecal: 20% via biliary excretion.
Category C
Category C
Opioid Analgesic
Opioid Analgesic